Learning from East to West and vice versa: Clinical epidemiology of colorectal cancer in China

Winkels, Renate M.; Kampman, Ellen; Wu, Ming

doi:10.1002/cncr.33444

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidences of CRC and adenoma vary according to age, sex, and region. [9][10][11] To improve the time-and costeffectiveness of colonoscopy and reduce complications, it is worth discussing the age at which screening using colonoscopy is initiated in different regions and sexes.…”

Section: Introductionmentioning

confidence: 99%

Adenoma Detection Rate in Average-Risk Population: An Observational Consecutive Retrospective Study

Zhang

et al. 2023

Cancer Control

View full text Add to dashboard Cite

Background Although colonoscopy is considered the most effective tool for reducing colorectal cancer-related morbidity, the age at which average-risk individuals begin colonoscopic screening is undetermined. This study aimed to compare the adenoma and advanced adenoma detection rates according to age and sex in a large average-risk population in the rural areas of Eastern China. Methods This observational, single-center, retrospective study included patients with average colorectal cancer risk and examined the adenoma and advanced adenoma detection rates using age intervals of 5 years. We also compared the size and age of patients with and without advanced adenoma. Results We included 18 928 patients with a median age of 54 years (range 15–90 years), including 10 143 men and 8785 women. The adenoma and advanced adenoma detection rates were 17.08% and 5.24%, respectively, and increased with age in the whole population. The adenoma detection rates increased from 8.97% (aged 40–44) to 14.98% (aged 45–49) and 6.24% (aged 45–49) to 11.00% (aged 50–54) in men and women (both P < .001), respectively. The advanced adenoma detection rates increased from 2.19% (aged 40–44) to 4.76% (aged 45–49) and 1.89% (aged 45–49) to 3.13% (aged 50–54) in men ( P = .002) and women ( P = .056), respectively. Patients with advanced adenomas were significantly older than those with non-advanced adenomas ( P < .001). The tumors in the advanced adenoma group were significantly larger than those in the non-advanced adenoma group ( P < .001). Conclusion The adenoma and advanced adenoma detection rates increased significantly in average-risk population aged 45 years and older, especially in men.

show abstract

Section: Introductionmentioning

confidence: 99%

Adenoma Detection Rate in Average-Risk Population: An Observational Consecutive Retrospective Study

Zhang

et al. 2023

Cancer Control

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) is the second most common cause of cancer death worldwide 1 . In China, the incidence of colorectal cancer has been increasing, which is common in western nations 2 , 3 . Numerous studies have shown that CRC morbidity and mortality are closely related to the following factors: genetic variants 4 , race 5 , family 6 , age 7 , 8 , high fat intake 9 , 10 , red meat consumption, obesity 11 , alcohol consumption, smoking 12 , 13 and physical inactivity 14 , 15 .…”

Section: Introductionmentioning

confidence: 99%

Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo

Yin

Zhao

Gorja

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…The annual incidence and mortality rates of CRC have recently decreased in Western countries with improvements in early cancer prevention and treatment ( Siegel et al, 2018 ). However, in China, the incidence of CRC has been increasing annually owing to its aging population, industrialisation, and westernised diet ( Li and Gu, 2005 ; Winkels et al, 2021 ). Cancer Analysis (2015) released in 2016 ( Miller et al, 2016 ) showed that the incidence of gastrointestinal malignant tumours in China was 1,055.4 per 100,000, with a mortality rate of 689.0 per 100,000 individuals.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of jianpi huatan granule in reducing colorectal cancer metastasis and recurrence after radical resection and adjuvant chemotherapy: Study protocol for a randomised, double-blind, placebo-controlled, multicentre trial

Cui

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The high incidence and mortality rates of colorectal cancer (CRC) are a severe challenge in China. In patients with stage III and high-risk stage II CRC after radical resection and postoperative adjuvant chemoradiotherapy, 40–60% experience recurrence and metastasis. Several years of clinical practice have shown that traditional Chinese medicine, including Jianpi Huatan granule (JHG), effectively prevents stage III and high-risk stage II CRC recurrence and metastasis after radical resection and postoperative standard adjuvant chemotherapy. However, high-level systematic plans and evidence-based medicine are lacking in this regard. Therefore, this randomised control trial aimes to determine the efficacy of JHG in reducing stage III and high-risk stage II CRC metastasis and recurrence after radical resection and postoperative standard adjuvant chemotherapy.Methods: This is a multicentre, randomised, double-blind, placebo-controlled clinical trial. Three hundred and fifty patients with stage III or high-risk stage II CRC who completed adjuvant chemotherapy after radical resection will be recruited from eight medical centres in China and randomly assigned to test (n = 175) and control (n = 175) groups at a ratio of 1:1. The test group will receive oral JHG for 3 months, whereas the control group will receive oral placebo for 3 months. The primary outcomes will be the disease-free survival and 1-, 2-, and 3-years metastasis and recurrence rates, whereas the secondary outcomes will be quality of life and circulating tumour cells. The patients will be followed-up monthly during treatment and every 3–6 months thereafter until recurrence, metastasis, death, or the end of the study.Trial registration: This trial was registered at ClinicalTrials.gov (NCT03716063).

show abstract

Learning from East to West and vice versa: Clinical epidemiology of colorectal cancer in China

Cited by 4 publications

References 19 publications

Adenoma Detection Rate in Average-Risk Population: An Observational Consecutive Retrospective Study

Adenoma Detection Rate in Average-Risk Population: An Observational Consecutive Retrospective Study

Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo

Efficacy of jianpi huatan granule in reducing colorectal cancer metastasis and recurrence after radical resection and adjuvant chemotherapy: Study protocol for a randomised, double-blind, placebo-controlled, multicentre trial

Contact Info

Product

Resources

About